H.C. Wainwright initiated coverage on PharmAthene (NYSE: PIP) with a Buy rating and a price target of $4.00. Analyst Andrew ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE